Navigation Links
NeoStem's Denis Rodgerson, Ph.D. to Lecture on Stem Cells and Regenerative Medicine at University of Nevada Las Vegas Campus
Date:3/5/2008

NEW YORK, March 5 /PRNewswire-FirstCall/ -- NeoStem, Inc. (Amex: NBS), which is pioneering the pre-disease collection, processing and long-term storage of adult stem cells for future medical need, today announced that Denis Rodgerson, Ph.D., NeoStem's Director of Stem Cell Science will lecture at The University of Nevada Las Vegas campus this evening. In October 2007, NeoStem announced the expansion of its network of adult stem cell collection centers into Las Vegas, the first in the region.

Dr. Rodgerson's lecture, entitled, "Stem Cells & Regenerative Medicine: Past, Present & Future," will address the evolving nature of stem cell research and applications as well as NeoStem's proprietary Very Small Embryonic Like Stem Cells (VSELs) technology and its potential role in the market.

Dr. Rodgerson has published more than 150 articles in medical and scientific literature and is the holder of several patents. He is an inventor of the proprietary process that serves as the basis for NeoStem's platform stem cell collection business and was the founder of NeoStem's predecessor company. He has been a consultant to many institutions and corporations, including NASA, National Bureau of Standards, Hewlett Packard, and Beckman Instruments. Prior to founding NeoStem, Dr. Rodgerson founded StemCyte, Inc., an umbilical cord blood banking company, where he served as Chief Operating Officer and Senior Vice President until 2002. He is also Professor Emeritus of Pathology and Laboratory Medicine at the UCLA School of Medicine.

About NeoStem, Inc.

NeoStem is managing a growing nationwide network of adult stem cell collection centers, enabling people to donate and store their own (autologous) stem cells when they are young and healthy for their personal use in times of future medical need. The Company has also recently entered the research and development and therapeutic arenas, through the acquisition of a worldwide exclusive license to an early-stage technology to identify and isolate rare stem cells from adult human bone marrow, called VSELs (very small embryonic- like stem cells), which have been shown to have several physical characteristics that are generally found in embryonic stem cells.

Forward-Looking Statements

Certain statements in this press release constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including statements concerning the ability of NeoStem, Inc. ("the Company") to develop the adult stem cell business, to develop the VSEL technology, the future of regenerative medicine and the role of adult stem cells and VSELs in that future, the future use of adult stem cells and VSELs as a treatment option and the potential revenue growth of the Company's business. Such forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause the actual results, performance or achievements of the Company, or industry results, to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements. The Company's ability to enter the adult stem cell arena, its success in such arena and future operating results are dependent upon many factors, including but not limited to (i) the Company's ability to obtain sufficient capital or a strategic business arrangements to fund its expansion plans; (ii) the Company's ability to build the management and human resources and infrastructure necessary to support the growth of its business; (iii) competitive factors and developments beyond the Company's control; (iv) scientific and medical developments beyond the Company's control; (v) the Company's inability to obtain appropriate state licenses or any other adverse effect or limitations caused by government regulation of the business; (vi) whether any of the Company's current or future patent applications result in issued patents; and (vii) other risk factors discussed in the Company's periodic filings with the Securities and Exchange Commission.

Contact:

NeoStem, Inc.

Robin Smith, Chief Executive Officer

T: 212-584-4180

E: rsmith@neostem.com

http://www.neostem.com


'/>"/>
SOURCE NeoStem, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Human Genome Sciences Appoints Maxine Gowen, Ph.D., to Its Board Of Directors
2. BiPar Names Hoyoung Huh, M.D., Ph.D. President and Chief Executive Officer
3. Nektar Appoints Hoyoung Huh, M.D., Ph.D., to Serve on the Companys Board of Directors
4. Mersana Therapeutics, Inc. Appoints Chief Scientific Officer, Timothy B. Lowinger, Ph.D.
5. PharmAthene Enhances Executive Leadership Team and Appoints Joan Fusco, Ph.D. Senior Vice President of Operations
6. Koronis Pharmaceuticals Announces Appointment of Daniel H. Petree and George R. Painter, Ph.D. to Board of Directors
7. Cylene Pharmaceuticals Appoints Kenna Anderes, Ph.D. as Vice President of Cancer Biology
8. Neurocrine Announces Appointment of Kevin Gorman, Ph.D., as President and Chief Executive Officer
9. Neurobiological Technologies, Inc. Reports Retirement of Ronald E. Cape, Ph.D., from Board
10. WellGen, Inc. Names Nancy E. Rawson, Ph.D., Chief Scientific Officer
11. Sunesis Pharmaceuticals Appoints Lesley A. Stolz, Ph.D., Vice President, Corporate and Business Development
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/22/2017)...  Personal Genome Diagnostics Inc. (PGDx) today announced ... the U.S. Department of Veterans Affairs (VA) that ... company,s new CancerSELECT ™ 125 test. CancerSELECT ... test that includes microsatellite instability status (MSI), a ... checkpoint inhibitor immunotherapies. CancerSELECT 125 will be available ...
(Date:3/20/2017)... CA (PRWEB) , ... March ... ... are substances that interfere with the ability of endogenous hormones to regulate ... inhibiting ligand binding activity (antagonists), EDCs produce adverse reproductive, neurological, proliferative, and ...
(Date:3/20/2017)... ... March 20, 2017 , ... Charm Sciences, ... & play system that counts Peel Plate microbial test colonies, stores plate images, ... stand-alone unit has an internal computer, and is accurate within 10% of an ...
(Date:3/20/2017)... , March 20, 2017 Western Institutional Review ... ethical review of clinical research, announced today the launch ... (SRS) for NIH-funded multi-site research. As the ... institution clients, WIRB has an extensive background in reviewing ... status as the IRB of record for the majority ...
Breaking Biology Technology:
(Date:2/26/2017)...  Securus Technologies, a leading provider of civil ... investigation, corrections and monitoring, announces the appointment of ... "Too often, too many offenders return to jail ... trying to tackle this ongoing problem and improve ... members. While significant steps are underway, Securus continues to ...
(Date:2/22/2017)... 22, 2017 With the biometrics market ... identifies four technologies that innovative and agile startups ... share in the changing competitive landscape: multifactor authentication ...   "Companies can no longer afford ... says Dimitrios Pavlakis , Industry Analyst at ...
(Date:2/21/2017)... Der weltweite Biobanking-Sektor wird bis ... Gespräch mit mehr als 50 Vertretern aus verschiedenen Branchen wurde ... um diese Prognose zu realisieren. ... Zu den Schwierigkeiten ... Mittel für die Biobank, die Implementierung Zeit sparender Technologien, ...
Breaking Biology News(10 mins):